A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma
A phase 2 trial of Apalutamide in salivary gland cancers, run by Janssen Pharmaceutical K.K., active and no longer recruiting.
Overview
A Study of Apalutamide Combined With GnRH Agonist in Participants With Androgen Receptor Positive Salivary Gland Carcinoma is a phase 2 interventional study registered as NCT04325828 by Janssen Pharmaceutical K.K., with 31 participants enrolled, started 2020-04-07 and due to reach its primary completion in 2021-06-09. Interventions recorded: Apalutamide and GnRH Agonist. Results have been posted on the registry.
Similar pages
not linked directly; found by shared links- TrialA Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer
Shares Apalutamide and the tag pipeline.
- TrialClinical Trial of HG146 Administered to Participants with Adenoid Cystic Carcinoma
Shares Salivary gland cancers and the tag pipeline.
- TrialA Study of Apalutamide (ARN-509) in Men With Non-Metastatic Castration-Resistant Prostate Cancer
Shares Apalutamide and the tag pipeline.
- TrialA Study of Apalutamide in Participants With High-Risk, Localized or Locally Advanced Prostate Cancer Who Are Candidates for Radical Prostatectomy
Shares Apalutamide and the tag pipeline.
- TrialAn Efficacy and Safety Study of JNJ-56021927 (Apalutamide) in High-risk Prostate Cancer Subjects Receiving Primary Radiation Therapy: ATLAS
Shares Apalutamide and the tag pipeline.
- TrialAn Efficacy and Safety Study of Apalutamide (JNJ-56021927) in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone in Participants With Chemotherapy-naive Metastatic Castration-resistant Prostate Cancer (mCRPC)
Shares Apalutamide and the tag pipeline.
- TrialStudy of REM-422 in Patients With Recurrent, Metastatic, or Unresectable Adenoid Cystic Carcinoma
Shares Salivary gland cancers and the tag pipeline.
- TrialA Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Shares Salivary gland cancers and the tag pipeline.